All 107 biotech companies tracked
Every biotech company tracked here — 107 mid- and large-cap names, 83 with a dated clinical trial readout ahead. Trial dates from ClinicalTrials.gov, filings from SEC EDGAR. Each page lists that company's upcoming readouts, the
dates already passed, and the SEC filings where results get announced.
ACAD ACADIA Pharmaceuticals Inc.$4.3B · next readout August 2027 ADPT Adaptive Biotechnologies Corporation$3.6B · 1 trial record AGIO Agios Pharmaceuticals Inc.$2.2B · next readout March 2029 ALNY Alnylam Pharmaceuticals Inc.$32.5B · next readout April 2027 ALMS Alumis Inc.$3.6B · next readout December 2027 AMGN Amgen Inc.$239.2B · next readout December 2026 AMLX Amylyx Pharmaceuticals Inc.$2.0B · 1 trial record ACLX Arcellx Inc.acquired by Gilead Sciences, April 2026 RCUS Arcus Biosciences Inc.$3.6B · next readout April 2028 ARQT Arcutis Biotherapeutics Inc.$3.4B · next readout April 2028 ARNA Arena Pharmaceuticals Inc.acquired by Pfizer, March 2022 ARGX argenx SE$64.0B · next readout March 2027 ATAI AtaiBeckley Inc.$2.6B · 2 trial records AXSM Axsome Therapeutics Inc.$11.4B · next readout December 2026 BLTE Belite Bio Inc$6.0B · next readout June 2027 BIIB Biogen Inc.$32.7B · next readout December 2026 BHVN Biohaven Ltd.$2.2B · next readout December 2026 BMRN BioMarin Pharmaceutical Inc.$13.4B · next readout April 2027 BNTX BioNTech SE$28.4B · next readout April 2027 BPMC Blueprint Medicines Corporationacquired by Sanofi, July 2025 CELC Celcuity Inc.$4.0B · next readout January 2028 CLDX Celldex Therapeutics Inc.$2.8B · next readout June 2028 CNTA Centessa Pharmaceuticals plcacquired by Eli Lilly, June 2026 CGON CG Oncology, Inc.$6.1B · next readout March 2027 CRNX Crinetics Pharmaceuticals Inc.$8.8B · next readout May 2027 CRSP CRISPR Therapeutics AG$4.5B · next readout July 2028 DCPH Deciphera Pharmaceuticals Inc.acquired by Ono Pharmaceutical, June 2024 DFTX Definium Therapeutics Inc.$4.7B · next readout September 2027 DNLI Denali Therapeutics Inc.$3.7B · next readout December 2026 DNTH Dianthus Therapeutics Inc.$5.7B · next readout December 2026 IRON Disc Medicine Inc.$2.8B · next readout May 2027 DYN Dyne Therapeutics Inc.$4.5B · next readout July 2028 EWTX Edgewise Therapeutics Inc.$4.4B · next readout January 2027 ELVN Enliven Therapeutics Inc.$3.2B · next readout December 2028 ERAS Erasca Inc.$6.5B · next readout April 2028 EXEL Exelixis Inc.$13.5B · next readout December 2026 GILD Gilead Sciences Inc.$183.0B · next readout December 2026 GKOS Glaukos Corporation$9.0B · next readout April 2027 GRFS Grifols S.A.$5.2B · next readout September 2027 HALO Halozyme Therapeutics Inc.$9.7B · next readout March 2028 HRMY Harmony Biosciences Holdings Inc.$2.0B · next readout April 2027 COAG Hemab Therapeutics Holdings Inc.$2.2B · next readout July 2027 IDYA IDEAYA Biosciences Inc.$3.1B · next readout January 2027 IBRX ImmunityBio Inc.$7.4B · next readout March 2027 IMVT Immunovant Inc.$8.1B · next readout May 2027 INCY Incyte Corporation$26.0B · next readout December 2026 INDV Indivior Pharmaceuticals Inc.$5.1B · 1 trial record INSM Insmed Incorporated$28.5B · next readout December 2026 IONS Ionis Pharmaceuticals Inc.$9.3B · next readout December 2026 JAZZ Jazz Pharmaceuticals plc$16.4B · next readout December 2026 KLRA Kailera Therapeutics Inc.$2.3B · next readout May 2027 KNSA Kiniksa Pharmaceuticals International plc$4.8B · next readout December 2027 KOD Kodiak Sciences Inc$2.6B · next readout February 2027 KRYS Krystal Biotech Inc.$9.9B · next readout December 2026 KYMR Kymera Therapeutics Inc.$9.1B · next readout June 2027 KYKOF Kyowa Kirin Co. Ltd.$7.6B · next readout March 2027 LNTH Lantheus Holdings Inc.$6.8B · next readout August 2027 LEGN Legend Biotech Corporation$4.1B · 2 trial records LGND Ligand Pharmaceuticals Incorporated$6.0B · next readout April 2027 LQDA Liquidia Corporation$7.7B · next readout February 2027 LBPH Longboard Pharmaceuticals Inc.acquired by Lundbeck, December 2024 MDGL Madrigal Pharmaceuticals Inc.$12.5B · next readout December 2026 MBX MBX Biosciences Inc.$3.0B · next readout January 2028 MRUS Merus N.V.acquired by Genmab, December 2025 MLYS Mineralys Therapeutics Inc.$2.2B · 1 trial record MIRM Mirum Pharmaceuticals Inc.$6.9B · next readout January 2027 MRNA Moderna Inc.$69.6B · next readout January 2027 NKTR Nektar Therapeutics$2.4B · next readout May 2028 NBIX Neurocrine Biosciences Inc.$15.8B · next readout February 2027 NAMS NewAmsterdam Pharma Company N.V.$3.5B · next readout November 2027 NVCR NovoCure Limited$2.1B · next readout October 2028 NRIX Nurix Therapeutics Inc.$2.4B · next readout January 2028 NUVL Nuvalent Inc.acquired by GSK, July 2026 NUVB Nuvation Bio Inc. Class A$2.2B · 2 trial records ORKA Oruka Therapeutics Inc.$5.6B · next readout October 2027 PHVS Pharvaris N.V.$2.4B · next readout June 2027 PRAX Praxis Precision Medicines Inc.$9.1B · next readout December 2026 PTGX Protagonist Therapeutics Inc.$8.8B · 3 trial records PTCT PTC Therapeutics Inc.$6.4B · next readout September 2027 REGN Regeneron Pharmaceuticals Inc.$84.0B · next readout December 2026 RLAY Relay Therapeutics Inc.$3.5B · next readout April 2028 RYTM Rhythm Pharmaceuticals Inc.$7.0B · next readout March 2027 ROIV Roivant Sciences Ltd.$27.0B · 0 trial records SRRK Scholar Rock Holding Corporation$5.7B · 3 trial records SLS SELLAS Life Sciences Group Inc.$2.1B · next readout December 2026 SION Sionna Therapeutics Inc.$2.1B · 1 trial record SWTX SpringWorks Therapeutics Inc.acquired by Merck KGaA, July 2025 SYRE Spyre Therapeutics Inc.$9.0B · next readout June 2027 GPCR Structure Therapeutics Inc.$3.5B · 1 trial record SUPN Supernus Pharmaceuticals Inc.$2.7B · next readout December 2026 TARS Tarsus Pharmaceuticals Inc.$2.5B · next readout December 2026 TFX Teleflex Incorporated$5.8B · 1 trial record TLX Telix Pharmaceuticals Limited$3.5B · next readout January 2027 TERN Terns Pharmaceuticals Inc.acquired by Merck & Co., May 2026 TGTX TG Therapeutics Inc.$8.6B · next readout January 2027 TVTX Travere Therapeutics Inc.$5.3B · next readout March 2027 TRVI Trevi Therapeutics Inc.$2.5B · next readout August 2027 RARE Ultragenyx Pharmaceutical Inc.$2.6B · next readout January 2027 UTHR United Therapeutics Corporation$22.7B · next readout December 2026 PCVX Vaxcyte Inc.$7.9B · next readout December 2027 VERA Vera Therapeutics Inc.$2.5B · next readout November 2027 VCYT Veracyte Inc.$4.5B · 1 trial record MANE Veradermics Incorporated$4.6B · next readout December 2026 VRTX Vertex Pharmaceuticals Inc.$139.9B · next readout January 2027 VKTX Viking Therapeutics Inc.$4.0B · next readout July 2027 XENE Xenon Pharmaceuticals Inc.$6.3B · next readout January 2027 ZLAB Zai Lab Limited$2.2B · next readout March 2027
Trial data from ClinicalTrials.gov
(U.S. National Library of Medicine); filings from
SEC EDGAR — U.S.
government works in the public domain. Information only, not investment advice.